CDK4 and cancer: The intervention of CDKs has been a hot topic in cancer therapy, among which inhibitors that block the activity of CDK4 and CDK6 enzymes (CDK4/6) have been approved by the FDA to treat metastatic hormone receptor-positive breast cancer (4).